Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.
Gilbert LazarusRefael Alfa BudimanIkhwan RinaldiPublished in: Cancer immunology, immunotherapy : CII (2021)
This project has been prospectively registered at PROSPERO (registration ID: CRD42020202142) on 4 August 2020.